Zobrazeno 1 - 10
of 74
pro vyhledávání: '"Angela M Minassian"'
Autor:
Kathryn Milne, Alasdair Ivens, Adam J Reid, Magda E Lotkowska, Aine O'Toole, Geetha Sankaranarayanan, Diana Munoz Sandoval, Wiebke Nahrendorf, Clement Regnault, Nick J Edwards, Sarah E Silk, Ruth O Payne, Angela M Minassian, Navin Venkatraman, Mandy J Sanders, Adrian VS Hill, Michael Barrett, Matthew Berriman, Simon J Draper, J Alexandra Rowe, Philip J Spence
Publikováno v:
eLife, Vol 10 (2021)
Falciparum malaria is clinically heterogeneous and the relative contribution of parasite and host in shaping disease severity remains unclear. We explored the interaction between inflammation and parasite variant surface antigen (VSA) expression, ask
Externí odkaz:
https://doaj.org/article/70c326d1e81641cbb27a268a47c79208
Autor:
Francisco J. Martinez, Michael White, Micheline Guillotte-Blisnick, Christèle Huon, Alix Boucharlat, Fabrice Agou, Patrick England, Jean Popovici, Mimi M. Hou, Sarah E. Silk, Jordan R. Barrett, Carolyn M. Nielsen, Jenny M. Reimer, Paushali Mukherjee, Virander S. Chauhan, Angela M. Minassian, Simon J. Draper, Chetan E. Chitnis
Publikováno v:
npj Vaccines, Vol 9, Iss 1, Pp 1-11 (2024)
Abstract The receptor-binding domain, region II, of the Plasmodium vivax Duffy binding protein (PvDBPII) binds the Duffy antigen on the reticulocyte surface to mediate invasion. A heterologous vaccine challenge trial recently showed that a delayed do
Externí odkaz:
https://doaj.org/article/4ef9c0cbceda4b979429052cf23a7f55
Autor:
Magali Matsumiya, Elena Stylianou, Kristin Griffiths, Zoe Lang, Joel Meyer, Stephanie A Harris, Rosalind Rowland, Angela M Minassian, Ansar A Pathan, Helen Fletcher, Helen McShane
Publikováno v:
PLoS ONE, Vol 8, Iss 7, p e67922 (2013)
A better understanding of the relationships between vaccine, immunogenicity and protection from disease would greatly facilitate vaccine development. Modified vaccinia virus Ankara expressing antigen 85A (MVA85A) is a novel tuberculosis vaccine candi
Externí odkaz:
https://doaj.org/article/58cafdfb650f4af69c100d33f85ac92f
Preclinical development of an in vivo BCG challenge model for testing candidate TB vaccine efficacy.
Publikováno v:
PLoS ONE, Vol 6, Iss 5, p e19840 (2011)
There is an urgent need for an immunological correlate of protection against tuberculosis (TB) with which to evaluate candidate TB vaccines in clinical trials. Development of a human challenge model of Mycobacterium tuberculosis (M.tb) could facilita
Externí odkaz:
https://doaj.org/article/eff730226a814080a95b3a71d0dd8150
Autor:
Kristin L Griffiths, Ansar A Pathan, Angela M Minassian, Clare R Sander, Natalie E R Beveridge, Adrian V S Hill, Helen A Fletcher, Helen McShane
Publikováno v:
PLoS ONE, Vol 6, Iss 8, p e23463 (2011)
Vaccination with Bacille Calmette-Guérin (BCG) has traditionally been used for protection against disease caused by the bacterium Mycobacterium tuberculosis (M.tb). The efficacy of BCG, especially against pulmonary tuberculosis (TB) is variable. The
Externí odkaz:
https://doaj.org/article/3909a8979d79483eb237d71a5dbfb29a
Autor:
Jordan R. Barrett, Sarah E. Silk, Catherine G. Mkindi, Karolina M. Kwiatkowska, Mimi M. Hou, Amelia M. Lias, Wilmina F. Kalinga, Ivanny M. Mtaka, Kirsty McHugh, Martino Bardelli, Hannah Davies, Lloyd D. W. King, Nick J. Edwards, Virander S. Chauhan, Paushali Mukherjee, Stella Rwezaula, Chetan E. Chitnis, Ally I. Olotu, Angela M. Minassian, Simon J. Draper, Carolyn M. Nielsen
Publikováno v:
Frontiers in Immunology, Vol 14 (2024)
We have previously reported primary endpoints of a clinical trial testing two vaccine platforms for the delivery of Plasmodium vivax malaria DBPRII: viral vectors (ChAd63, MVA), and protein/adjuvant (PvDBPII with 50µg Matrix-M™ adjuvant). Delayed
Externí odkaz:
https://doaj.org/article/1d778520743644f7bdf485e7bb8929be
Autor:
Kazutoyo Miura, Ababacar Diouf, Michael P. Fay, Jordan R. Barrett, Ruth O. Payne, Ally I. Olotu, Angela M. Minassian, Sarah E. Silk, Simon J. Draper, Carole A. Long
Publikováno v:
Malaria Journal, Vol 22, Iss 1, Pp 1-14 (2023)
Abstract Background For blood-stage malaria vaccine development, the in vitro growth inhibition assay (GIA) has been widely used to evaluate functionality of vaccine-induced antibodies (Ab), and Plasmodium falciparum reticulocyte-binding protein homo
Externí odkaz:
https://doaj.org/article/97da816f826f4510910320fa9d5e35e6
Autor:
Florian A. Bach, Diana Muñoz Sandoval, Michalina Mazurczyk, Yrene Themistocleous, Thomas A. Rawlinson, Adam C. Harding, Alison Kemp, Sarah E. Silk, Jordan R. Barrett, Nick J. Edwards, Alasdair Ivens, Julian C. Rayner, Angela M. Minassian, Giorgio Napolitani, Simon J. Draper, Philip J. Spence
Publikováno v:
The Journal of Clinical Investigation, Vol 133, Iss 20 (2023)
BACKGROUND The biology of Plasmodium vivax is markedly different from that of P. falciparum; how this shapes the immune response to infection remains unclear. To address this shortfall, we inoculated human volunteers with a clonal field isolate of P.
Externí odkaz:
https://doaj.org/article/d31b6e682890476cba7fb42065b54f54
Autor:
Carolyn M. Nielsen, Jordan R. Barrett, Christine Davis, Jonathan K. Fallon, Cyndi Goh, Ashlin R. Michell, Catherine Griffin, Andrew Kwok, Carolin Loos, Samuel Darko, Farida Laboune, Mehmet Tekman, Ababacar Diouf, Kazutoyo Miura, Joseph R. Francica, Amy Ransier, Carole A. Long, Sarah E. Silk, Ruth O. Payne, Angela M. Minassian, Douglas A. Lauffenburger, Robert A. Seder, Daniel C. Douek, Galit Alter, Simon J. Draper
Publikováno v:
JCI Insight, Vol 8, Iss 2 (2023)
Modifications to vaccine delivery that increase serum antibody longevity are of great interest for maximizing efficacy. We have previously shown that a delayed fractional (DFx) dosing schedule (0-1-6 month) — using AS01B-adjuvanted RH5.1 malaria an
Externí odkaz:
https://doaj.org/article/55c02c635c8641a881c121cc4f81a7fc
Autor:
Wanlapa Roobsoong, Anjali Yadava, Simon J. Draper, Angela M. Minassian, Jetsumon Sattabongkot
Publikováno v:
Frontiers in Immunology, Vol 13 (2023)
Controlled Human Malaria Infection models (CHMI) have been critical to advancing new vaccines for malaria. Stringent and safe preparation of a challenge agent is key to the success of any CHMI. Difficulty producing the Plasmodium vivax parasite in vi
Externí odkaz:
https://doaj.org/article/d6af9fa210144f1ab47c65ebb1329058